Ahmad FB, Cisewski JA, Anderson RN. Leading causes of death in the US, 2019–2023. JAMA. 2024.

Article  PubMed  Google Scholar 

Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the World. Glob Heart. 2024;19(1):11.

Article  PubMed  PubMed Central  Google Scholar 

Fonarow GC, Kosiborod MN, Rane PB, Nunna S, Villa G, Habib M, et al. Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease. Clin Cardiol. 2021;44(10):1457–66.

Article  PubMed  PubMed Central  Google Scholar 

Colantonio LD, Shannon ED, Orroth KK, Zaha R, Jackson EA, Rosenson RS, et al. Ischemic event rates in very-high-risk adults. J Am Coll Cardiol. 2019;74(20):2496–507.

Article  PubMed  Google Scholar 

Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167–76.

Article  CAS  PubMed  Google Scholar 

Behan SA, Mulder H, Rockhold FW, Gutierrez JA, Baumgartner I, Katona BG, et al. Impact of polyvascular disease and diabetes on limb and cardiovascular risk in peripheral artery disease. J Am Coll Cardiol. 2022;79(17):1781–3.

Article  PubMed  Google Scholar 

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.

Article  CAS  PubMed  Google Scholar 

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52.

Article  CAS  PubMed  Google Scholar 

Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, et al. Association of Interleukin 6 receptor variant with cardiovascular disease effects of Interleukin 6 receptor blocking therapy: a phenome-wide Association study. JAMA Cardiol. 2018;3(9):849–57.

Article  PubMed  PubMed Central  Google Scholar 

Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M. Interleukin-6 Signaling effects on ischemic stroke and other Cardiovascular outcomes: a mendelian randomization study. Circ Genom Precis Med. 2020;13(3):e002872.

Article  PubMed  PubMed Central  Google Scholar 

Georgakis MK, Malik R, Li X, Gill D, Levin MG, Vy HMT, et al. Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association study. Circulation. 2021;143(11):1177–80.

Article  CAS  PubMed  Google Scholar 

Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.

Article  PubMed  Google Scholar 

Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.

Article  PubMed  Google Scholar 

Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–89.

Article  CAS  PubMed  Google Scholar 

Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos JA, Seshadri S, et al. Circulating Interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98(10):e1002–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akita K, Isoda K, Sato-Okabayashi Y, Kadoguchi T, Kitamura K, Ohtomo F, et al. An Interleukin-6 receptor antibody suppresses atherosclerosis in Atherogenic Mice. Front Cardiovasc Med. 2017;4:84.

Article  PubMed  PubMed Central  Google Scholar 

Kobara M, Noda K, Kitamura M, Okamoto A, Shiraishi T, Toba H, et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res. 2010;87(3):424–30.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.

Article  CAS  PubMed  Google Scholar 

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28.

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.

Article  CAS  PubMed  Google Scholar 

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.

Article  CAS  PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139(25):e1082–143.

Google Scholar 

Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of Dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50.

Article  PubMed  Google Scholar 

Nayor M, Brown KJ, Vasan RS. The molecular basis of predicting Atherosclerotic cardiovascular disease risk. Circul Res. 2021;128(2):287–303.

Article  CAS  Google Scholar 

Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022;23(21):12906.

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Dhalla NS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci. 2024;25(2):1082.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, Cancino-Arenas N, Hernandez-Vargas F, Troncoso R, et al. Role of Interleukin-6 in vascular health and disease. Front Mol Biosci. 2021;8:641734.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su JH, Luo MY, Liang N, Gong SX, Chen W, Huang WQ, et al. Interleukin-6: a novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130.

Article  PubMed  PubMed Central  Google Scholar 

Didion SP. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int J Mol Sci. 2017;18(12):2563.

Article  PubMed  PubMed Central  Google Scholar 

Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A. Systematic review on the role of IL-6 and IL-1β in Cardiovascular diseases. J Cardiovasc Dev Disease. 2024;11(7):206.

Article  CAS